AIM ImmunoTech (NYSEAMERICAN:AIM) Shares Down 7.8% – Time to Sell?

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was down 7.8% on Monday . The stock traded as low as $0.26 and last traded at $0.2630. Approximately 1,836,691 shares traded hands during trading, an increase of 48% from the average daily volume of 1,242,926 shares. The stock had previously closed at $0.2854.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets decreased their price target on AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $9.00.

AIM ImmunoTech Stock Performance

The stock has a market cap of $3.74 million, a P/E ratio of -0.08 and a beta of 1.20. The firm has a 50 day moving average of $0.33 and a two-hundred day moving average of $0.58. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.01 and a current ratio of 1.01.

AIM ImmunoTech (NYSEAMERICAN:AIM) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.43) EPS for the quarter. The firm had revenue of $0.03 million during the quarter. On average, research analysts predict that AIM ImmunoTech Inc. will post -0.63 EPS for the current fiscal year.

Hedge Funds Weigh In On AIM ImmunoTech

A hedge fund recently bought a new position in AIM ImmunoTech stock. Corient Private Wealth LLC purchased a new position in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 10,001 shares of the company’s stock, valued at approximately $87,000. Corient Private Wealth LLC owned about 1.31% of AIM ImmunoTech at the end of the most recent reporting period. Institutional investors own 12.02% of the company’s stock.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.